Therefore, during the pathological process of secondary cardiac insufficiency caused by MT, drugs that can effectively inhibit the release of the inflammatory mediator TNF-α and the production of superoxide anion are desired for effectively reducing myocardial cell apoptosis and improving heart function, and thus improving the survival rate of patients with MT. The gene discussed is TNF; the disease is cancer.